[{"id":"6ec566d0-9d3a-4e78-841c-c1a61a7e011e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04121442","created_at":"2021-01-18T20:08:24.419Z","updated_at":"2024-07-02T16:35:55.034Z","phase":"Phase 1/2","brief_title":"Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors","source_id_and_acronym":"NCT04121442","lead_sponsor":"Buzzard Pharmaceuticals","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e isunakinra (EBI-005)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2023-02-21"}]